Glob­al Blood Ther­a­peu­tics poised to sub­mit ap­pli­ca­tion for ac­cel­er­at­ed ap­proval, with new piv­otal da­ta on its sick­le cell dis­ease drug

Glob­al Blood Ther­a­peu­tics is set to sub­mit an ap­pli­ca­tion for ac­cel­er­at­ed ap­proval in the sec­ond-half of this year, af­ter un­veil­ing fresh da­ta from a late-stage tri­al that showed just over half the pa­tients giv­en the high­est dose of its ex­per­i­men­tal sick­le cell dis­ease drug ex­pe­ri­enced a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in oxy­gen-wield­ing he­mo­glo­bin, meet­ing the study’s main goal.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN